Leech Platelet Aggregation Inhibitor 2
Secondary RGD-motif platelet-aggregation inhibitor reported from the leech salivary secretome — family member with decorsin / ornatin.
Preclínico / mecanísticoLast updated: 2026-05-26 · Reviewed by ASH Editorial Board
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Secondary RGD-motif platelet-aggregation inhibitor reported from the leech salivary secretome — family member with decorsin / ornatin.
- Evidence level
- In vitro
- Drug vs leech
- Purified natural compound
- Safety domains
- Bleeding
Clinical translation limit
RGD-motif platelet inhibition by leech peptides does NOT establish clinical efficacy. No FDA-approved derivative exists; the marketed GPIIb/IIIa antagonist eptifibatide is derived from snake-venom barbourin, not from leech.
Molecular Profile
- Category
- Antiplatelet
- Evidence tier
- Preclinical
- Molecular weight
- 4,000 Da
- Source species
- Hirudo medicinalis
- Discovered
- 2018
Biological Targets
- → platelet integrin αIIbβ3 (GPIIb/IIIa) via RGD motif
External Resources
Related Antiplatelet Compounds
Calin
Anti-platelet adhesion protein that blocks von Willebrand factor–collagen binding.
Saratin
Anti-platelet adhesion protein blocking collagen-mediated platelet activation.
Decorsin
RGD-containing peptide inhibiting platelet GP IIb/IIIa receptor — eptifibatide ancestor.
Ornatin
RGD-peptide GP IIb/IIIa antagonist — sister molecule to decorsin from a different leech species.